Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst Transfer Cycles With Low Progesterone on Day of Embryo Transfer

NCT04806919 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04806919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04806919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst Transfer Cycles With Low Progesterone on Day of Embryo Transfer
Lead sponsor
University Hospital, Ghent
Phase
Phase 3
Overall status
Completed
Start date
April 2, 2021
Completion date
March 31, 2025
Enrollment
87 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

embryo loss, ivf, luteal phase defect